Imran Siddiqui, MD
Internal Medicine · Temple, TXNPI 1821050238
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations.
Across 54 payments — averaging $26.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$244
- Johnson & Johnson$177
- Abbott$170
- Boehringer Ingelheim$121
- Lilly USA, LLC$92
- Merck$83
- plus $532 from 14 others
Across 1,854 payments — averaging $382.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$563K
- Boehringer Ingelheim$67K
- AstraZeneca$40K
- Argenx US, Inc.$17K
- Sanofi US Services Inc.$13K
- Janssen Research & Development, LLC$7K
- plus $3K from 2 others
What the payments were for
- Food & beverage$1,418100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 12 | $244 |
| Johnson & Johnson | 1 | $177 |
| Abbott | 2 | $170 |
| Boehringer Ingelheim | 6 | $121 |
| Lilly USA, LLC | 4 | $92 |
| Merck | 5 | $83 |
| Astellas Pharma US Inc | 3 | $71 |
| Pfizer | 3 | $60 |
| Biohaven Pharmaceuticals, Inc. | 2 | $58 |
| Viiv Healthcare Company | 2 | $54 |
| Exact Sciences | 2 | $48 |
| Amgen | 3 | $44 |
| GSK | 2 | $37 |
| Inspire Medical Systems, Inc. | 1 | $35 |
| Gilead | 1 | $25 |
| Smith+Nephew | 1 | $22 |
| La Jolla Pharmaceutical Company | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| BD | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEREPAK$177
- Confirm Rx$145
How this compares
$1,418 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 33 | $47,557 |
| JardianceEmpagliflozin | 27 | $39,439 |
| OzempicSemaglutide | 35 | $36,542 |
| EntrestoSacubitril/Valsartan | 24 | $24,935 |
| FarxigaDapagliflozin Propanediol | 24 | $22,774 |
| MounjaroTirzepatide | 19 | $21,925 |
| XareltoRivaroxaban | 16 | $18,579 |
| JanuviaSitagliptin Phosphate | 12 | $16,229 |
| TrulicityDulaglutide | 14 | $13,104 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 156 | $4,312 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 73 | $2,085 |
| Rosuvastatin Calcium | 171 | $1,865 |
| Levothyroxine Sodium | 160 | $1,632 |
| Pregabalin | 43 | $1,554 |
| Atorvastatin Calcium | 198 | $1,415 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $60 | $47,55733 claims |
| Boehringer IngelheimJardiance | $121 | $39,43927 claims |
| Novo NordiskOzempic | $244 | $36,54235 claims |
| Lilly USA, LLCMounjaro, Trulicity | $92 | $35,02933 claims |
| Johnson & JohnsonXarelto | $177 | $18,57916 claims |
| MerckJanuvia | $83 | $16,22912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Temple
- Hameed AliTemple$773K
- Catherine McNealTemple$187K
- Timothy MillerTemple$146K
- Michael VolkTemple$65K
- Spencer BerthelsenSugar Land$891K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.